Alnylam Gives Updates on Hemophilia, ATTR Programs; Adds HBV to Pipeline | GenomeWeb

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week unveiled initial top-line data from an ongoing Phase I study of its siRNA-based hemophilia drug ALN-AT3, which showed the drug is capable of significantly knocking down its target after a single, subcutaneous dose.

Alnylam also announced that it has expanded its pipeline to include a hepatitis B program, which it acquired when it bought the RNAi assets of Merck earlier this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of some animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.